# Rezdiffra (resmetirom) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/resmetirom

> The FDA approved Rezdiffra (resmetirom), sponsored by MADRIGAL PHARMACEUTICALS, INC. (MDGL), on March 14, 2024 for with noncirrhotic MASH with moderate to advanced liver fibrosis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Rezdiffra (resmetirom) FDA approved?

Yes. The FDA approved Rezdiffra (resmetirom), sponsored by MADRIGAL PHARMACEUTICALS, INC. (MDGL), on March 14, 2024 for with noncirrhotic MASH with moderate to advanced liver fibrosis. FDA novel drug approvals: "Rezdiffra | resmetirom | 3/14/2024 | To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarringPress ReleaseDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/resmetirom)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/resmetirom#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Rezdiffra (resmetirom) |
| Codes | MGL-3196 |
| Sponsor | MADRIGAL PHARMACEUTICALS, INC. (MDGL) https://sec-api.dev/companies/mdgl/catalysts |
| Indications | with noncirrhotic mash with moderate to advanced liver fibrosis, with mash with moderate to advanced liver fibrosis, with noncirrhotic mash with moderate to, with, [MASH - Metabolic Dysfunction-Associated Steatohepatitis](https://sec-api.dev/indications/mash-metabolic-dysfunction-associated-steatohepatitis), [Non-Alcoholic Fatty Liver Disease](https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease), [NASH - Nonalcoholic Steatohepatitis](https://sec-api.dev/indications/nash-nonalcoholic-steatohepatitis), MASH |
| Modality |  |
| FDA designations | accelerated, priority review |

## Timeline

### March 14, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with noncirrhotic MASH with moderate to advanced liver fibrosis.
- First seen 2025-02-26, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Rezdiffra | resmetirom | 3/14/2024 | To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarringPress ReleaseDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA217785 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240314, review_priority PRIORITY; sponsor_name MADRIGAL; product REZDIFFRA (RESMETIROM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217785%22
- SEC Form 10-Q (accession 0001628280-26-069145): "On March 14, 2024, the Company announced that the FDA granted accelerated approval of Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/mdgl-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-050845): "On March 14, 2024, the Company announced that the FDA granted accelerated approval of Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." https://www.sec.gov/Archives/edgar/data/1157601/000162828026050845/mdgl-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-030947): "On March 14, 2024, the Company announced that the FDA granted accelerated approval of Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." https://www.sec.gov/Archives/edgar/data/1157601/000162828026030947/mdgl-20260331.htm
- SEC Form 10-K (accession 0001628280-26-009514): "On March 14, 2024, the Company announced that the FDA granted accelerated approval of Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to" https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-048559): "On March 14, 2024, the Company announced that the FDA granted accelerated approval of Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." https://www.sec.gov/Archives/edgar/data/1157601/000162828025048559/mdgl-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-037613): "On March 14, 2024, the Company announced that the FDA granted accelerated approval of Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." https://www.sec.gov/Archives/edgar/data/1157601/000162828025037613/mdgl-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-021356): "On March 14, 2024, the Company announced that the FDA granted accelerated approval of Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." https://www.sec.gov/Archives/edgar/data/1157601/000162828025021356/mdgl-20250331.htm
- SEC Form 10-K (accession 0001628280-25-007980): "On March 14, 2024, the Company announced that the U.S. Food and Drug Administration ("FDA") granted accelerated approval of Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with" https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-035787): "In March 2024, Madrigal announced FDA approval of Rezdiffra for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/d924231dex991.htm
- SEC Form 10-K (accession 0001628280-25-007980): "•In March 2024, we announced that the FDA granted accelerated approval of Rezdiffra in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm

### Feb 2025: interim data readout

- Status: completed, met. Date confidence: month. Stage: 2.
- First seen 2025-03-13, last confirmed 2025-03-13.
- SEC Form 10-K (accession 0001493152-25-010146): "In addition, in February 2025, Akero Therapeutics announced preliminary topline results with Efruxifermin (EFX) showing statistically significant reversal of compensated cirrhosis (F4) due to MASH at week 96 in their Phase 2b SYMMETRY study." https://www.sec.gov/Archives/edgar/data/1535955/000149315225010146/form10-k.htm

### February 26, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-02-26, last confirmed 2025-02-26.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-035787): "Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis" https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/d924231dex991.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: NASH; Cirrhosis, Liver.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05500222 (A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT05500222

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: NASH; Cirrhosis, Liver.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05500222 (A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT05500222

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-Alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04951219 (A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT04951219

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-Alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04951219 (A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT04951219

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: NASH - Nonalcoholic Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03900429 (A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT03900429

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: NASH - Nonalcoholic Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03900429 (A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT03900429

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: MASH - Metabolic Dysfunction-Associated Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07335601 (Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07335601

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: MASH - Metabolic Dysfunction-Associated Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07335601 (Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07335601

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07763015 (Study of Resmetirom in Children and Adolescents With MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07763015

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07763015 (Study of Resmetirom in Children and Adolescents With MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07763015

## Same indication

- [Lanifibranor](https://sec-api.dev/pdufa/lanifibranor) (IVA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/resmetirom.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Rezdiffra (resmetirom) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/resmetirom

```bibtex
@misc{secapidev_pdufa_resmetirom_20261116,
  title        = {Rezdiffra (resmetirom) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/resmetirom}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_resmetirom_20261116","title":"Rezdiffra (resmetirom) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/resmetirom","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
